Antibody (Suitable for clinical applications)
Sample Type: FFPE Patient Samples.
Tested Applications: IHC. Approved for In Vitro Diagnostic Procedures on FFPE tissues. For tissue collection recommendations, please see datasheet sent with product.
Application Notes
| Specification | Recommendation |
|---|---|
| Recommended Dilution (Conc) | 1:10-1:20 |
| Pretreatment | Citrate Buffer pH 6.0 |
| Incubation Parameters | 30 min at Room Temperature |
Prior to use, inspect vial for the presence of any precipitate or other unusual physical properties. These can indicate that the antibody has degraded and is no longer suitable for patient samples. Please run positive and negative controls simultaneously with all patient samples to account and control for errors in laboratory procedure. Use of methods or materials not recommended by enQuire Bio including change to dilution range and detection system should be routinely validated by the user.
Clonality: Monoclonal
Anti-O-Methylguanine-DNA-Methyltransferase Antibody Clone: MT3.1
Host and Isotype: Mouse IgG1
Recommended Positive Control Sample: Tonsil
Cellular Localization of Antibody MT3.1 Staining: Cytoplasmic, nuclear
Buffer and Stabilizer: PBS with 1% BSA and 0.05% NaN3
Antibody Concentration: Lot specific. Plese contact tech support for data.
Immunogen: Recombinant human MGMT protein.
Storage Conditions: This antibody should be stored refrigerated (2-8°C). This product should not be used past the expiration date printed on the vial.
O-Methylguanine-DNA-Methyltransferase Information for Pathologists
Summary:
O6-methylguanine-DNA methyltransferase, a DNA repair enzyme at 10q26. Removes DNA alkylation adducts from mutagenic O(6)-methylguanine, which both:. Repairs damaged DNA and protects normal cells from carcinogens, and. Contributes to drug resistance of gliomas to alkylating agents by protecting tumor cells from alkylating agents such as temozolomide. MGMT promoter hypermethylation and epigenetic silencing often occur as early events in carcinogenesis.Notable Clinical Features:
General. Polymorphisms in MGMT gene may be cancer risk factor (Tumour Biol 2013;34:3227). CNS, diffuse glioma and glioblastoma:. Methylation of promoter region of MGMT is associated with favorable outcome in glioblastoma patients undergoing chemotherapy with alkylating agents (median survival 22 months with versus 13 months without methylated promoter) (Onco Targets Ther 2013;6:1363). Methylation may not have favorable outcome in glioblastoma patients >50 years of age (Mod Pathol 2013;26:922), although recommended to consider use of temozolamide in elderly regardless of MGMT status (Clin Neurol Neurosurg 2013;115:1375, PLoS One 2013;8:e74242).Common Uses By Pathologists:
Methylation status may be useful to oncologists planning treatment . Microscopic (histologic) images Images hosted on other servers:. Missing Image. Hepatocellular carcinoma with HIV (fig A / B).Limitations and Warranty
This antibody is manufactured in accordance with clinical good manufacturing practices in an ISO13485:2016 certified production facility. It is intended for multiple uses including in vitro diagnostic use and research use only applications. Please see vial label for expiration date. We strive to always deliver antibodies with a shelf life of at least two years.
There are no reviews yet.